Navigation Links
MEDRAD Molecular Imaging Earns Top Rank in Innovation

New technology reduces radiation exposure, eliminates workflow complexity, and enables patient-scheduling flexibility

WARRENDALE, Pa., Feb. 13 /PRNewswire/ -- MEDRAD's Intego(TM) PET Infusion System has been named one of Medical Imaging Magazine's top eight most innovative products of the year. The magazine designated its top eight based on what its readership considers to be the most far-reaching, game changing or otherwise groundbreaking medical devices on the market.

(Logo: )

MEDRAD's Intego PET Infusion System automatically measures and delivers patient-specific Fluorodeoxyglucose (FDG) doses on demand. With on-board dosimetry, the system can deliver precise, repeatable FDG doses within +/- 2% of the measured dose. The Intego also minimizes FDG handling and is fully shielded, reducing radiation exposure by more than 20% compared to conventional (syringe-based) FDG delivery methods.

"Intego technology is raising the standard of care in FDG delivery," says Doug Descalzi, Executive Director of MEDRAD's Molecular Imaging business. "Healthcare professionals gain precision, flexibility and control over workflow, which can help any PET practice grow clinically and safely."

More detailed information on MEDRAD's Intego PET Infusion System is available at


MEDRAD, Inc., is a worldwide leading provider of medical devices and services that enable and enhance imaging and therapeutic procedures of the human body. For diagnostic imaging, MEDRAD's product offerings include a comprehensive line of vascular injection systems, magnetic resonance (MR) surface coils and patient care products, and equipment services. The company also offers products used in vascular intervention. MEDRAD's total 2007 revenues were $525 million. In 2003, MEDRAD received the Malcolm Baldrige National Quality Award, the top honor a U.S. company can receive for quality and business excellence. The company's world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD is an affiliate of Bayer AG. More company information is available at

The Bayer Group is a global enterprise with core competencies in the fields of healthcare, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma AG. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at

Cautionary statement regarding forward-looking statements.

Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and MEDRAD's plans and objectives to differ materially from those expressed or implied in the forward-looking statements. MEDRAD, INC. undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.

Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MEDRAD Announces eCoil(TM) for Siemens, Philips 3.0T MR Scanners
2. MEDRAD Plant Named IndustryWeek Magazine Award Finalist
3. MEDRAD Mobile MR Injector Meets Challenges of MR Trailers
4. MEDRAD(R) Revenues Grow 10 Percent in 2007
5. MEDRAD and PETNET Solutions Partner for Innovative FDG Delivery
6. MEDRAD Receives FDA 510(k) Clearance for Wireless MR Infusion System
7. MEDRAD Multi Vendor Service Forms Alliance with Wetsco
8. MEDRAD Builds on Success of P3T Cardiac CT Injection Software
9. MEDRAD Sponsors PET Research with University of Zurich
10. A new molecular zip code, and a new drug target for Huntingtons disease
11. New knock-out gene model provides molecular clues to breast cancer
Post Your Comments:
(Date:6/27/2016)... ... , ... TherapySites, the leading website and online ... Counseling Association. This new relationship allows TherapySites to continue to extend their ... benefits and promotional offers. , "TCA is extremely excited about this new partnership, ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in ... ways they remain in the eye of the beholder, according to experts who offered ... The American Journal of Managed Care. For the full issue, click here . ...
(Date:6/26/2016)... NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and ... to be personalized through a fitness app. The fitness app plans to fix the two ... currently only offer a one size fits all type program , They don’t ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 ... brings up a new, often overlooked aspect of head lice: the parasite’s ability to live ... not a common occurrence, but a necessary one in the event that lice have simply ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
Breaking Medicine Technology: